I-Mab stock price target raised to $9 from $7 at BTIG on strategic shift

Biotech firm I-Mab (NASDAQ:IMAB) is undergoing a major strategic transformation, rebranding as NovaBridge Biosciences to become a diversified global platform, supported by CBC Group, and pursuing a dual listing on the Hong Kong Stock Exchange. This strategic repositioning, alongside pipeline advancements for key assets like Givastomig, has driven a stock surge of over 37% in the past week and prompted multiple analyst upgrades, including BTIG raising its price target to $9.00 with a Buy rating. These initiatives are expected to enhance operational focus and access to Asian capital markets, with the company's financial health rated as excellent.

Analysis

I-Mab (NASDAQ:IMAB) is undergoing a significant strategic transformation, rebranding as NovaBridge Biosciences and shifting from a single-asset oncology developer to a diversified global biotechnology platform. This repositioning, supported by CBC Group and a planned dual listing on the Hong Kong Stock Exchange, has driven a stock surge of over 37% in the past week. Analyst firms have responded positively, with BTIG raising its price target to $9.00 from $7.00 and Jefferies to $10, both maintaining Buy ratings.

The company's financial health is rated as EXCELLENT by InvestingPro, underscored by a strong current ratio of 22.8, indicating robust liquidity. The appointment of Kyler Lei, a former Sino Biopharm and WuXi Apptec executive, as CFO, alongside the leadership of chairman Fei Wu, signals a strengthened management team. These moves are expected to enhance operational focus and facilitate access to Asian capital markets.

Key pipeline assets show promising advancement, with Givastomig progressing towards a global Phase 2 trial in Q1 2026 for metastatic gastric cancer, following positive Phase 1b data showing an 83% objective response rate in combination therapies. Additionally, VIS-101 is anticipated to deliver a final Phase 2 readout in Q4 2025. These clinical developments, coupled with the strategic overhaul, underpin the optimistic outlook from analysts.

Key Decisions for Investors

• Monitor the progress of the strategic transformation, particularly the shareholder approval for rebranding and the dual listing on the Hong Kong Stock Exchange, as these could unlock further capital and market exposure.
• Evaluate the clinical trial advancements for Givastomig and VIS-101, especially the upcoming Phase 1b topline data and Phase 2 readouts, which are critical catalysts for future valuation.
• Consider the company's strong financial health (excellent rating, current ratio of 22.8) and the support from CBC Group as foundational strengths, but remain vigilant for execution risks associated with such a significant corporate restructuring.